RecruitingNot ApplicableNCT02605785
A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy
Sponsor
Mayo Clinic
Enrollment
332 participants
Start Date
Nov 1, 2015
Study Type
INTERVENTIONAL
Conditions
Summary
This study is designed to learn more about overall tau burden in the brain of patients with Progressive Supranuclear Palsy (PSP).
Eligibility
Min Age: 35 Years
Inclusion Criteria8
- Must be over 35 years of age and present with gradual progression of PSP-related symtoms
- Must have an informant or study partner that can provide independent information of functioning.
- Must meet criteria for possible or probable Progressive Supranuclear Palsy. To fulfill criteria for possible PSP, subjects must have a gradually progressive disorder with either vertical (upward or downward) supranuclear palsy or both slowing of vertical saccades and prominent postural instability with falls in the first year of disease onset. To fulfill criteria for probable PSP, subjects must have vertical (upward or downward gaze) supranuclear palsy and prominent postural instability with falls in the first year of disease onset.
- Subjects with concurrent illnesses that could account for their symptoms, such as traumatic brain injury, encephalitis, strokes or developmental syndromes will be excluded.
- Women that are pregnant or post-partum and breast-feeding will be excluded.
- Subjects will be excluded from the study if they have any of the following genetic conditions which can increase the chance of cancer: Cowden disease, Lynch syndrome, hypogammaglobulinemia, Wiskott-Aldrich syndrome, and Down's syndrome.
- Subjects will also be excluded if MRI is contraindicated (metal in head, cardiac pace maker, e.t.c.), if there is severe claustrophobia, if there are conditions that may confound brain imaging studies (e.g. structural abnormalities, including subdural hematoma, intracranial neoplasm or large cortical infarcts), or if they are medically unstable or are on medications that might affect brain structure or metabolism (e.g. chemotherapy).
- Subjects will also be excluded if they do not have an informant, or do not consent to research.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGF-18 AV 1451
Tau PET scan
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT02605785
Related Trials
Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
NCT032251441 location
Facilitating Diagnostics and Prognostics of Parkinsonian Syndromes Using Neuroimaging
NCT038721021 location
tDCS as Treatment for Motor Function
NCT072916871 location
Improving Prognostic Confidence in Neurodegenerative Diseases Causing Dementia Using Peripheral Biomarkers and Integrative Modeling
NCT065297444 locations
Gait Analysis in Neurological Disease
NCT029947191 location